The atrial natriuretic peptide genetic ariant rs5068 is associated with a favorable cardiometabolic phenotype in a mediterranean population

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2850-2856

  Cannone, Valentina ^a   Cefalu, Angelo Baldassare ^b   Noto, Davide ^b   Scott, Christopher G ^a   Bailey, Kent R ^a   Cavera, Giovanni ^c   Pagano, Michele ^d   Sapienza, Michelangelo ^c   Averna, Maurizio R ^b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^d Ospedale GF Ingrassia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC PHENOTYPE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHENOTYPE; PREVALENCE; SEX DIFFERENCE; SOUTHERN EUROPE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHENOTYPE;

EID: 84886379425     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2337     Document Type: Article

References (38)

1. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984;247:F863-F866
2. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14: 1345-1351
3. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122: 1022-1036
4. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005;90: 3622-3628
5. Polak J, Kotrc M, Wedellova Z, et al. Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol 2011;58: 1119-1125
6. Galitzky J, Sengenès C, Thalamas C, et al. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 2001;42: 536-544
7. Moro C, Pillard F, de Glisezinski I, et al. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am J Physiol Regul Integr Comp Physiol 2007; 293:R612-R617
8. Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003; 278: 48617-48626
9. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109: 594-600
10. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS.Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals.Circulation 2007;115: 1345-1353
11. Wang TJ. The natriuretic peptides and fat metabolism. N Engl J Med 2012;367: 377-378
12. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011;96: 3242-3249
13. NemerM, Chamberland M, Sirois D, et al. Gene structure of human cardiac hormone precursor, pronatriodilatin. Nature 1984;312: 654-656
14. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 2009;11: 35-42
15. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41: 348-353
16. Ellis KL, Newton-Cheh C, Wang TJ, et al. Association of genetic variation in the natriuretic peptide systemwith cardiovascular outcomes. JMolCellCardiol 2011;50: 695-701
17. Maimaitiming S, Roussel R, Hadjadj S, et al.; D.E.S.I.R. Study Group. Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study. J Hypertens 2010;28: 1230-1233
18. Cannone V, Boerrigter G, Cataliotti A, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 2011;58: 629-636
19. Noto D, Cefalù AB, Barbagallo CM, et al. Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population. Nutr Metab Cardiovasc Dis 2009;19: 321-326
20. Barbagallo CM, Cavera G, Sapienza M, et al. Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. Int J Obes Relat Metab Disord 2001;25: 185-190
21. Lohman T. Anthropometric Standardization Reference Manual. Champaign, IL, Human Kinetics Books, 1988
22. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502
23. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. Geneva, World Health Organization, 1982
24. Walker AE, Robins M, Weinfeld FD. The National Survey of Stroke.Clinical findings. Stroke 1981;12(2 Pt. 2 Suppl 1):I13-I44
25. World Health Organization, International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a World Health Organization/International Diabetes Federation Consultation. Geneva, World Health Org., 2006
26. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157: 2413-2446
28. corrected in: Arch Intern Med 1998; 158:573
29. Barbee RW, Perry BD, Ré RN, Murgo JP, Field LJ. Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ Res 1994;74: 747-751
30. Melo LG, Veress AT, Ackermann U, Pang SC, Flynn TG, Sonnenberg H. Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept 1999;79: 109-115
31. Sarzani R, Paci VM, Dessì-Fulgheri P, Espinosa E, Rappelli A. Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. J Hypertens Suppl 1993;11:S214-S215
32. Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19: 581-585
33. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/cGMP- dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009;58: 2880-2892
34. Dessì-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997;15: 1695-1699
35. Sarzani R, Paci VM, Zingaretti CM, et al. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J Hypertens 1995;13: 1241-1246
36. Sarzani R, Dessì-Fulgheri P, Salvi F, et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999;17: 1301-1305
37. Sarzani R, Strazzullo P, Salvi F, et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 2004;12: 351-356
38. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. JAmColl Cardiol 2012; 60: 2305-2312